Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 29Carcinoma, Transitional Cell 25Urinary Bladder Neoplasms 24Neoplasms 22Carcinoma, Merkel Cell 20Neoplasm Metastasis 18Carcinoma, Renal Cell 17Colorectal Neoplasms 16Breast Neoplasms 16Squamous Cell Carcinoma of Head and Neck 15Ovarian Neoplasms 14Triple Negative Breast Neoplasms 11Pancreatic Neoplasms 9Melanoma 9Head and Neck Neoplasms 8Stomach Neoplasms 7Recurrence 6Carcinoma, Hepatocellular 6Ureteral Neoplasms 5Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Urethral Neoplasms 4Sarcoma 4Neuroendocrine Tumors 4Leukemia, Myeloid, Acute 4Glioblastoma 4Carcinoma, Squamous Cell 4Uterine Cervical Neoplasms 3Turcot syndrome 3Skin Neoplasms 3

Interventions

Gemcitabine 60Cisplatin 38Oxaliplatin 30Capecitabine 28Fluorouracil 21Leucovorin 19pembrolizumab 11Irinotecan 11durvalumab 9130-nm albumin-bound paclitaxel 9Erlotinib Hydrochloride 8Trastuzumab 7Bevacizumab 7Platinum 6Magnetic Resonance Spectroscopy 6Albumin-Bound Paclitaxel 61,2-diaminocyclohexaneplatinum II citrate 6Taxes 5Specimen Handling 5Sorafenib 5Radiotherapy 5Carboplatin 5Docetaxel 4Biopsy 4trifluridine tipiracil drug combination 3dehydroftorafur 3atezolizumab 3Paclitaxel 3Lapatinib 3Interleukin-12 Subunit p35 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gallbladder Neoplasms × avelumab × Clear all
NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡